PDCD1 and metastatic malignant neoplasm in the lymph nodes: Compared with the other two groups, the BSC group tended to have more patients with age ≥ 65, female, ECOG ≥ 2, gastric and GEJ cancer, distant lymph node metastasis, and primary resistance to prior anti-PD1/PD-L1 monotherapy (Table 1).